Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus NICARDIPINE HYDROCHLORIDE IN 0 86 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus NICARDIPINE HYDROCHLORIDE IN 0 86 SODIUM CHLORIDE.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes, leading to vasodilation and reduced myocardial contractility.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion: initial rate 5 mg/hour, titrate by 2.5 mg/hour every 15 minutes as needed up to 15 mg/hour. For acute hypertension, 5 mg/hour initial, increase by 2.5 mg/hour every 5-15 minutes to maximum 15 mg/hour.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life is 2 to 4 hours; prolonged in hepatic impairment or with continuous infusion.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 35% of metabolites.
Category C
Category A/B
Electrolyte
Electrolyte